

PRESS RELEASE –

May 15, 2017

Texas A&M University System (TAMUS) and Greffex, Inc. Sign Agreement to collaborate on advanced process and manufacturing development.

Texas A&M University System (TAMUS), through its Health Science Center's Center for Innovation in Advanced Development and Manufacturing (CIADM), and Greffex, Inc., an Aurora, Colorado-based biotechnology company and developer of vaccines have entered into a Master Research Agreement in order to further research and development of Greffex vaccines.

The Greffex vaccine program is based on the company's proprietary GREVAX™ platform—a highly scalable process that also safeguards vaccine purity. Developed with the support of the National Institutes of Health and the National Institute of Standards and Technology, GREVAX™ vaccines are designed as small synthetic nanoparticles of genes packaged in adenoviral shells that can be modified to deliver genetic payloads wherever most beneficial. GREVAX™ vaccines target cells that kick start the immune system and do not need chemical adjuvants. These vaccines are a clean product that do not expose vaccine recipients to unwanted genetic by-products and more efficiently support a rapid response to an epidemic, such as pandemic influenza.

“As we prepare for the next phase of research and development, we needed a creative, innovative “university-based” partner to assist us in our long-range development plans,” said John R. Price, President and CEO of Greffex, “and in Texas A&M Health Science Center's Center for Innovation in Advanced Development and Manufacturing (CIADM), we found the creative, forward-thinking researchers who can leverage the resources of the entire university system.”

The Texas A&M Center for Innovation in Advanced Development and Manufacturing (Texas A&M CIADM) is part of a national strategy recommended in the August 2010 Public Health Emergency Medical Countermeasures Enterprise Review.

As one of three centers established as a public-private partnership to develop and manufacture countermeasures, the Texas A&M Center for Innovation will respond to the need for rapid and flexible manufacturing to bolster the nation's ability to respond to any attack or threat, including novel, previously unrecognized, naturally occurring emerging infectious diseases, as well as various chemical, biological, radiological and nuclear threats. It is designed to facilitate rapid research and development (R&D), promote novel product development through both public and private partnerships, ensure domestic manufacturing surge capacity, assist in FDA approval of products, as well as mentor the next generation of public health professionals through workforce training and outreach.

Greffex has a vibrant pipeline of vaccines currently undergoing testing. Originally created for H1N1 swine influenza and now preparing to enter clinical trials with its H5N1 avian influenza vaccine, the company has 11 vaccines ready for testing including Zika, Mers CoV, Dengue vaccine, an Ebola vaccine, and H7N9 avian influenza vaccine. Greffex vaccines are fast to create and produce inexpensively, efficient to manufacture and address worldwide health concerns.

For more information about Greffex and its GREVAX™ vaccines, please go to: www.greffex.com or contact John R. Price at jprice@greffex.com/866-723-4884

For more information about Texas A&M University System (TAMUS) Health Science Center and the Center for Innovation in Advanced (CIADM), please go to <https://ciadm.tamhsc.edu> or contact Jay Treat [wjtrear@tamhsc.edu](mailto:wjtreat@tamhsc.edu) / 979-436-0685